Navigation Links
Simple idea to dramatically improve dengue vaccinations

An innovative new study explains, for the first time, the failure of previous attempts to vaccinate against the four known Dengue viruses, and it suggests a very simple solution ?injecting the four vaccines simultaneously at different locations on the body.

A mosquito-born disease, Dengue kills tens of thousands of people per year and sickens 100 million more. Known as "bone-break disease," Dengue is characterized by excruciating pain and was "the most important mosquito-borne viral disease affecting humans" in 2005 according to the U.S. Centers for Disease Control.

The study, from bioengineers and physicists at Rice University, appears in the March 24 issue of the journal Vaccine. The study suggests that the multi-site vaccination strategy, termed polytopic vaccination, may be effective against other diseases as well, including HIV and cancer.

Dengue infection occurs from one of four closely related viruses. Previous exposure to one of the four ?either by prior infection or by vaccination ?makes people significantly more likely to develop a potentially lethal hemorrhagic infection if they are later infected by one of the other three viruses.

"This is a classic case of something called 'original antigenic sin,' which happens when our immune system becomes overly reliant upon memory when recognizing diseases similar to those that it has seen before," said lead researcher Michael Deem, the John W. Cox Professor in Biochemical and Genetic Engineering and professor of physics and astronomy. "With diseases like HIV, influenza and Dengue, our acquired immune system's tendency to go-with-what-it-knows can leave us more vulnerable to infection from a mutant strain or a related virus. The immune system may respond less favorably in these cases than if it had never been exposed to the disease in the first place."

Original antigenic sin, or immunodominance, arises out of the procedure the immune system uses to target infection. This start
'"/>

Source:Rice University


Page: 1 2 3

Related biology news :

1. Simple drug has the potential to save many lives threatened by malaria
2. Discovery Promises Simpler Therapy for Sickle Cell Disease
3. Simple sea sponge helps scientists understand tissue rejection
4. Simple explanation for complex pattern of feather development
5. Simple home spit test to spot deadly pre-eclampsia
6. New miniaturised chip dramatically reduces time taken for DNA analysis
7. Caloric restriction wont dramatically extend life span in humans: UCLA research
8. Hospitalizations because of chicken pox down dramatically since implementation of vaccine
9. Lack of a key enzyme dramatically increases resistance to sepsis
10. Smoking ban dramatically reduces air pollution in Irish pubs
11. Growing nerve cells in 3-D dramatically affects gene expression

Post Your Comments:
(Date:11/23/2009)...for 360 million years and survived when the dinosa...g to make many of them extinct, according to an ar... . , The fungus, Batrachochytrium dendrobatidi...amphibian extinctions in Central America and north...350 amphibian species by penetrating their skin, b...
(Date:11/23/2009)...x-week-old turkey poults could save millions of ma...ccording to Dr. Gerald Steiner from the Dresden Un...eir use of infrared spectroscopy to determine the ...accurate method with the potential to be used by t... eggs for breeding. The pilot study has just been ...
(Date:11/23/2009)... Interuniversity Professorship in Law and the Huma...of the Basque Country. The Professorship is largel...ch as researchers in the fields of molecular biolo...he Interuniversity Professorship in Law and the Hu...Basque Country was created in 1993. The worldwide ...
Breaking Biology News(10 mins):Rescuing male turkey chicks 2Research and legislation should go hand in hand, as much as possible 2Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 1Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 2Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 3Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 4Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 5Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 6Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 7Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 8Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 9Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 10Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 11Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 12Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 13Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 14Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 15Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 16Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 17Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 1Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 3Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 1Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 2Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 3Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 4
...in, reward and addictive behaviors. Opioids exert ... receptors, mu, delta and kappa whose genes have b...Opioid receptors in the brain are activated by a f...orphins and endorphin, which are released by neuro...usly by alkaloid opiates, the prototype of which i...
...ry J. Hannon, Ph.D., Cold Spring Harbor Laboratory...ute (HHMI) investigator, along with two other youn...rial Sloan-Kettering Cancer Centers (MSKCC) 2007 P... named after Paul A. Marks, Ph.D., President Emeri... to the basic understanding and treatment of cance...
...m aimed at linking together the world,s databases ... the Nobel Prize for Medicine awarded to Mario R. ... launched this week. , The Cambridge University... will ultimately support new medical advances and ...esearch. , Because they are so genetically simila...
Other Biology News:How does the opioid system control pain, reward and addictive behavior? 2How does the opioid system control pain, reward and addictive behavior? 3How does the opioid system control pain, reward and addictive behavior? 4Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer 2A computer for your mouse! 2
(Date:11/24/2009)...leEnergyCorp.announcedtodaythatthecompanyandtheOde...rded$2millionbyWashingtonState,sCommunityEconomicR...iptoconstructthestate,sfirstspecialtybiochemicalbi...willsignificantlyspeedthedevelopmentofourbiorefine...MarbleEnergyCEOKellyOgilvie."WearegratefultotheGov...
(Date:11/24/2009)...patientswithadvanced-stage,orrecurrentendometrialc...ll/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ)(the...nendocrinetherapyandoncology,todayannouncedpositiv...xicpeptideconjugate,AEZS-108(formerlyAN-152),inpat...ersonalizedhealthcareapproach,thestudyselectedpati...
(Date:11/24/2009)...ll/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglobalsp...tithassubmittedaMAAtotheEuropeanMedicinesAgencyfor...erapyindevelopment,forthetreatmentofType1Gaucherdi...ucerasealfathathasbeensubmitted,withprevious,submi...lobalsupplyshortageofthecurrentlyapprovedandmarket...
(Date:11/24/2009)...-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX )toda...hairman,willpresentatthe21stAnnualPiperJaffrayHeal...009at10:00a.m.ET. ,, Toaccesstheliveandsubseque...torRelationssectionofGenomicHealth,swebsiteat http...ebsiteatleast15minutespriortothebeginningofthepres...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2
...need is a good idea to make some good money. You c...me registration for a year for much less than $1 a...per month. For an additional $3 a month, get an en...fer secure online credit-card transactions. Cha-ch...n in for free. In principle you will have almost t...
...s. The Madison police department has moved to sp...ddition of an eToken USB key system provided by A...vide a robust and dependable situation thats easil...focus on protecting the city of Madison with unpar...on, said Neil Sullivan, the companys enterprise se...
...fices are located in the MG&E Innovation Center at...al research group ConjuGon announced on Tuesday ...of $1.1 million dollars from angel investors, incl...e new funds will be directed to the firms operatin...otheraputic treatments. , ,ConjuGon develops remed...
Other Biology Technology:The Wal-Mart-ization of e-commerce 2The Wal-Mart-ization of e-commerce 3Madison police adopt digital lock and key 2ConjuGon lands $1 million angel investment 2
Rabbit Anti-Potassium Channel kv3.2 Antibody, Unconjugated from Spring Bioscience
Sheep Anti-Human ErbB 2 Polyclonal Antibody, Unconjugated from Abcam
Hybridization Solution, 2 Concentrate, Buffered with SSPE from Sigma-Aldrich
Rabbit Anti-Rat Potassium Channel Kv2.2 Antibody, Unconjugated from CHEMICON
Biology Products: